CD101 and central nervous system cancer: The results consistently showed that glioma patients with a higher CD101 expression had a significantly deteriorative OS compared to those with a low CD101 level, including the subgroup of age >60 (Figure 4A), subgroup of age ≤60 (Figure 4B), subgroup of IDH mutation (Figure 4C), subgroup of 1p/19q non-codeletion (Figure 4D), subgroup of WHO grade 2 (Figure 4E), subgroup of WHO grade 3 (Figure 4F), subgroup of astrocytoma (Figure 4G), subgroup of CR (Figure 4H), and subgroup of PD&SD&PR (Figure 4I).